MRI Reporting

mpMRI prostate

Report 4 of 6

Zones and sectors, PSA density, PI-RADS v2.1 in the peripheral and transition zones, and staging; the case: a PI-RADS 5 lesion.

0:00 / 0:00
INDEX
ON THIS PAGE
  1. 1The clinician
  2. 2Anatomy
  3. 3The report
  4. 4Full report
  5. 5Pitfalls

What the clinician needs to know

The clinician here is the urologist, and the prostate cancer team. Your report must answer four questions.

  1. Is there a lesion that is likely to be significant cancer?
  2. Where exactly is it, so that a biopsy can target it?
  3. Has it spread beyond the prostate, into the fat or the seminal vesicles?
  4. And are there suspicious nodes, or bone metastases?

Anatomy and types

  • The prostate has four zones: the peripheral zone, at the back and sides, where most cancers start; the transition zone, around the urethra, where BPH grows; the central zone, at the base; and the anterior fibromuscular stroma, in front.
  • From top to bottom, the gland has a base, a mid-gland and an apex. PI-RADS splits each level into sectors, so every lesion has an address.
  • Measure the gland in three directions and multiply by 0.52, for its volume. The PSA divided by the volume is the PSA density: above 0.15 is a warning sign.
  • On T2, the normal peripheral zone is bright, and cancer is dark. On diffusion, cancer is dark on the ADC map, and bright on the high b value image, of at least 1400.
  • PI-RADS scores each lesion from 1 to 5: how likely it is to be clinically significant cancer, meaning Gleason 3 + 4 or more.
  • In the peripheral zone, diffusion decides. Normal scores 1; a linear or wedge-shaped area, 2; a focal area, but not marked on both maps, 3.
  • Focal and marked on both, dark on ADC and bright on high b value, scores 4; and 5 if it is 1.5 cm or more, or goes beyond the gland.
  • Dynamic contrast only breaks a tie: in the peripheral zone, a 3 that enhances early and focally becomes a 4.
  • In the transition zone, T2 decides. A round, fully encapsulated nodule scores 1; a mostly encapsulated one, 2; a heterogeneous area with blurred margins, 3.
  • A lens-shaped or ill-defined, homogeneous, moderately dark area scores 4; and 5 if it is 1.5 cm or more, or goes beyond the gland.
  • Here, diffusion can lift the score: a 2 becomes a 3 if diffusion scores 4 or 5, and a 3 becomes a 4 if diffusion scores 5.
  • Then the edge of the gland. Extraprostatic extension: a bulge or a break in the capsule, contact with it over 1 cm, an asymmetric neurovascular bundle, or an obliterated rectoprostatic angle.
  • Seminal vesicle invasion: dark T2 signal, restricted diffusion or enhancement in a vesicle, or tumour growing into it from the base.
  • Last, the pelvic nodes: over 8 mm in short axis is suspicious; and the bones, for metastases.

The report, in order

  1. Clinical: the PSA, and any previous biopsy, with its date.
  2. Technique: the scanner, the sequences with the highest b value, and the image quality.
  3. Gland: its three measurements, the volume, and the PSA density.
  4. Lesion: its address, by zone, side, level and sector; and its size, on ADC in the peripheral zone, on T2 in the transition zone.
  5. Score: what T2, diffusion and contrast show, and the PI-RADS score. In the UK, NICE also asks for a Likert score.
  6. Staging: extraprostatic extension and its side, the neurovascular bundles, and the seminal vesicles.
  7. Nodes and bones: the pelvic nodes, the bones, and the rest of the pelvis.
  8. Impression: the index lesion, with its score and its address, then the stage.
The headings in this order, each with what goes under it, ready to paste into your reporting system.

A full report

MRI PROSTATE · MULTIPARAMETRIC, 3 T · RAISED PSA, NO PREVIOUS BIOPSY

Clinical: PSA 8 ng/mL. No previous biopsy.

Technique: 3 T. T2, diffusion with b 1400, and dynamic contrast. Good image quality.

Gland: 5.0 × 3.7 × 4.2 cm, volume 40 mL. PSA density 0.20.

Lesion: left mid-gland, peripheral zone, posterolateral; 17 mm on ADC.

Score: dark on T2, markedly restricted on diffusion, with early focal enhancement. PI-RADS 5; Likert 5.

Staging: the lesion bulges the capsule, with 14 mm of contact: suspected left extraprostatic extension. Neurovascular bundles spared. Seminal vesicles clear.

Nodes and bones: no suspicious pelvic nodes. No bone metastases.

Impression: PI-RADS 5 lesion in the left mid-gland peripheral zone, with suspected extraprostatic extension: T3a N0 on MRI. Suitable for targeted biopsy.

Pitfalls

  • After a biopsy, blood is dark on T2 and can mimic tumour: look for it on T1, where it is bright.
  • The central zone is dark on T2 and ADC, at the base, on both sides: symmetry says it is normal.
  • Look hard at the front of the gland: anterior tumours hide among BPH nodules.
  • Give every lesion a full address: a lesion the urologist cannot find cannot be biopsied.

Sign in to keep track of the reports you have done.